GNS 561

Drug Profile

GNS 561

Alternative Names: GNS-561

Latest Information Update: 18 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genoscience
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Autophagy inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatocellular carcinoma

Most Recent Events

  • 24 Oct 2017 Genoscience plans a phase I/II trial for Hepatocellular carcinoma (Late-stage disease, Metastatic disease) in January 2018 (NCT03316222)
  • 05 Apr 2017 Pharmacodynamic and adverse events data from a preclinical trial in Hepatocellular carcinoma presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 05 Apr 2017 Pharmacodynamic results from a preclinical trial in Hepatocellular carcinoma presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top